Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.
